SBIR Phase II: Design and production of a next generation vaccine to prevent COVID

SBIR 第二阶段：设计和生产下一代预防新冠病毒的疫苗

• 批准号: 2313338
• 负责人: Peter Leonardi
• 金额: $ 99.77万
• 依托单位: OMNICYTE, LLC
• 依托单位国家: 美国
• 项目类别: Cooperative Agreement
• 财政年份: 2024
• 资助国家: 美国
• 起止时间: 2024-03-15 至 2025-08-31
• 项目状态: 未结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=2313338&HistoricalAwards=false
• 关键词: SBIR; Phase; II; Design; production

The broader impact of this Small Business Innovation Research (SBIR) Phase II project is to develop a next-generation COVID-19 vaccine that addresses the weaknesses of the current vaccines. While the current COVID-19 vaccines have saved countless lives and have allowed our society to get back to normal, they have their weaknesses. The boosters are sometimes not effective, and when they are, they have short-lived efficacy and they can have mild to severe side effects. These weaknesses not only put individuals at risk of getting sick with COVID or the side effects, but those weaknesses also compromise confidence in the vaccine, which affects compliance. The proposed project promises to produce a next-generation vaccine that has better efficacy and significantly reduced side effects, as well as increased duration of effectiveness. This could pave the way for an effective annual administration schedule of the vaccine booster that addresses new strains, much like the seasonal influenza vaccine. The proposed project intends to produce a next-generation vaccine that can renew confidence in vaccinating to prevent COVID-19. The project's objectives are to show that the vaccine candidate can not only create an immune response that can stop the spread of the virus but also kill the virus. Additionally, it is hoped that the project will show that the vaccine is safer than the current vaccines and that it promotes an immune response that lasts significantly longer than current vaccines. This will be accomplished by testing the vaccine in a Hamster model that simulates the human respiratory system well. Not only will efficacy be tested, but the longevity of the immune response will also be tested. As an additional objective of the study, the route of administration will be examined. The vaccine's effectiveness will be compared by administering it either through injection, nasal administration, or a microneedle patch.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.

这项小型企业创新研究（SBIR）II期项目的更广泛影响是开发下一代Covid-19疫苗，以解决当前疫苗的弱点。尽管目前的Covid-19疫苗挽救了无数的生命，并使我们的社会恢复正常，但它们的弱点。 助推器有时无效，当它们具有短寿命的功效时，它们可能会产生轻度至严重的副作用。这些弱点不仅使个人有生病或副作用生病的风险，而且这些弱点也损害了对疫苗的信心，这会影响依从性。拟议的项目有望生产一种下一代疫苗，该疫苗具有更好的功效和显着降低的副作用，并增加了有效性的持续时间。这可以为解决新菌株的疫苗助推器的有效年度管理时间表铺平道路，就像季节性流感疫苗一样。拟议的项目旨在生产下一代疫苗，该疫苗可以更新疫苗接种以防止COVID-19。该项目的目标是表明候选疫苗不仅可以产生免疫反应，从而阻止病毒的传播，还可以杀死病毒。此外，希望该项目能够表明该疫苗比目前的疫苗更安全，并且可以促进免疫反应的持续时间明显长于目前的疫苗。这将通过在模拟人类呼吸系统的仓鼠模型中测试疫苗来实现。不仅可以测试疗效，而且还将测试免疫反应的寿命。作为研究的另一个目标，将检查管理途径。通过注射，鼻腔给药或微针贴剂对疫苗进行管理，将进行疫苗的有效性。该奖项反映了NSF的法定任务，并被认为是值得通过基金会的知识分子和更广泛影响的评估评估的评估值得支持的。